TribLIVE

| USWorld


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

'Reverse vaccine' for diabetes passes test

Daily Photo Galleries

By The Los Angeles Times
Saturday, June 29, 2013, 6:57 p.m.
 

LOS ANGELES — A “reverse vaccine” that allows people with Type 1 diabetes to produce their own insulin has passed its first test with human subjects, according to a new study. The success points to a potential strategy for treating those in the early stages of the disease, experts said.

The therapy is designed to protect cells in the pancreas that make insulin, a hormone the body needs to convert sugars and starches into energy. In people with Type 1 diabetes, the immune system goes haywire and attacks those crucial insulin-producing cells for reasons that medical researchers don't understand.

Researchers dubbed the treatment a reverse vaccine because it suppresses the immune system, instead of stimulating it. As hoped, the experimental vaccine reduced the number of immune system “killer” cells that went on the attack.

“We're trying to turn off one specific immune response,” said Dr. Lawrence Steinman, an immunologist at Stanford University and senior author of the study published Wednesday in Science Translational Medicine.

About 1.25 million Americans have Type 1 diabetes.

 

 
 


Show commenting policy

Most-Read Nation

  1. Daughters more diligent than sons about elder care, study says
  2. Health care data breaches hit 30M patients and counting
  3. Scathing report says college trustees fail in mission
  4. Mortgage deal isn’t likely to cost $17B
  5. Cleanup follows heavy storms in Phoenix area
  6. Weight loss differs between the sexes
  7. Monsoon rains wreak havoc in Arizona
  8. Irwin native among military personnel kept waiting for return of personal vehicle
  9. Feds order 2nd autopsy in police shooting of black Missouri man
  10. Corruption trial focuses on wife of former Virginia governor
  11. Contraception, abstinence push U.S. teen birthrates to historic lows
Subscribe today! Click here for our subscription offers.